U.S. Online Retail and Ecommerce Stock News

OTCPK:BNCC
OTCPK:BNCCBanks

BNCCORP (OTCPK:BNCC) Margin Improvement Challenges Long Term Earnings Decline Narrative

BNCCORP (BNCC) has released its FY 2025 numbers with fourth quarter total revenue of US$9.4 million, basic EPS of US$0.62 and quarterly net income of US$2.2 million, set against a trailing twelve month picture that includes US$38.3 million of revenue and US$2.48 in EPS. Over recent periods the company has seen total revenue move from US$36.3 million to US$38.3 million on a trailing basis, while trailing EPS has shifted from US$2.24 to US$2.48. This gives investors a clearer sense of how the...
NYSE:CNK
NYSE:CNKEntertainment

Cinemark Holdings CNK Margin Slide Challenges Bullish Profitability Narratives After FY 2025 Q3 Results

Cinemark Holdings (CNK) has put up a mixed FY 2025 scorecard so far, with Q3 revenue of US$857.5 million and EPS of US$0.43, following Q2 revenue of US$940.5 million and EPS of US$0.81, and a Q1 loss of US$0.32 per share on revenue of US$540.7 million. The company has seen revenue move from US$734.2 million in Q2 2024 to US$921.8 million in Q3 2024, alongside EPS shifting from US$0.37 to US$1.54 over that stretch, so investors are likely to focus on how current margins stack up against that...
NasdaqGM:HRMY
NasdaqGM:HRMYPharmaceuticals

A Look At Harmony Biosciences (HRMY) Valuation After New FDA Approval Expands WAKIX Pediatric Use

Harmony Biosciences Holdings (HRMY) is back in focus after the FDA approved a supplemental new drug application for WAKIX, extending its use to treat cataplexy in pediatric narcolepsy patients aged six and older. See our latest analysis for Harmony Biosciences Holdings. Despite the fresh FDA approval, Harmony Biosciences’ share price has been under pressure in the short term, with a 1 day share price return of a 4.44% decline and a 7 day share price return of a 3.58% decline. Its 90 day share...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Moderna (MRNA) Valuation Check After Recent Share Price Surge And Pipeline Expectations

Why Moderna (MRNA) is on investors’ radar today Moderna (MRNA) has drawn fresh attention after recent share price moves, with the stock showing double digit returns over the past week, month, and past 3 months as investors reassess its mRNA pipeline and current valuation. See our latest analysis for Moderna. Beyond the recent bounce, Moderna’s share price has a 1-day return of 6.08% and a 90-day share price return of 108.41%. However, the 3-year total shareholder return of a 70.54% decline...
NYSE:COLD
NYSE:COLDIndustrial REITs

Barington Stake Puts Americold Valuation, Dividend And Turnaround In Focus

Barington Companies Management has taken a new significant position in Americold Realty Trust (NYSE:COLD). The stake signals potential activist interest in the company and its current direction. This development arrives as management has been discussing efforts to improve occupancy and stabilize earnings. For Americold Realty Trust, the timing of Barington's entry comes after a challenging share price stretch, with NYSE:COLD down 11.5% over the past month and 39.4% over the past year, and...
NYSE:ORCL
NYSE:ORCLSoftware

Oracle Lawsuits And Federal Wins Reframe AI Spending Risk For Investors

Oracle (NYSE:ORCL) faces multiple securities fraud class action lawsuits alleging it misled investors about risks and revenue expectations tied to its AI infrastructure spending. At the same time, Oracle has secured large federal contracts, including wins with the U.S. Air Force and the Centers for Medicare & Medicaid Services for Oracle Cloud services. Investors are weighing the company’s heavy AI and cloud capital expenditures, debt levels, and execution risks alongside these new...
NYSE:SMR
NYSE:SMRElectrical

Assessing NuScale Power (SMR) After A 33% One Year Share Price Decline

If you are wondering whether NuScale Power's current share price lines up with its underlying value, you are not alone and that is exactly what this article is here to unpack. The stock recently closed at US$14.20, with returns of 8.8% decline over 7 days, 29.7% decline over 30 days, 12.9% decline year to date and 32.8% decline over 1 year, set against a 38.5% return over 3 years and 31.5% over 5 years. These mixed returns sit against a backdrop of ongoing attention on NuScale Power's role...
NYSE:RTX
NYSE:RTXAerospace & Defense

RTX Weighs TFLN Opportunity Against Pratt And Whitney Engine Strain

Raytheon, part of NYSE:RTX, has received a contract to establish domestic production of thin film lithium niobate (TFLN) wafers in the US. The contract aims to strengthen supply security for critical defense and commercial technologies that rely on these advanced materials. Separately, Pratt & Whitney engine shortages are affecting Airbus A320 jet output, creating pressure across parts of the global aerospace supply chain. RTX sits at the intersection of defense electronics and commercial...
NYSE:ANF
NYSE:ANFSpecialty Retail

Abercrombie Kids Baby Line Launch Sparks Fresh Look At ANF Valuation

abercrombie kids, part of Abercrombie & Fitch, has launched its first Baby & Toddler Collection. The new line covers apparel for newborns through age 5, marking the brand's entry into this younger age group. Abercrombie & Fitch (NYSE:ANF) is adding a fresh product line at a time when its share price sits at $95.68. The stock has seen a 4.6% gain over the past week, very large multi year returns over 3 and 5 years, and a negative 9.0% return over the past year. This combination of shorter...
NYSE:EPAM
NYSE:EPAMIT

Is It Time To Reassess EPAM Systems (EPAM) After Prolonged Share Price Weakness

If you are wondering whether EPAM Systems is starting to look attractively priced, you are not alone. The recent share performance has many investors reassessing what the stock is really worth. The share price closed at US$167.69, with returns of a 5.8% decline over 7 days, 21.1% decline over 30 days, 16.3% decline year to date, 35.0% decline over 1 year, 46.1% decline over 3 years and 54.6% decline over 5 years. Recent headlines around EPAM Systems have focused on its role as a global...
NYSE:FDX
NYSE:FDXLogistics

FedEx Business Model Shift Puts Margins Valuation And Debt In Focus

FedEx (NYSE:FDX) is shifting its focus toward higher margin B2B logistics and premium direct-to-consumer services, while restructuring operations under its unified One FedEx model. The company is introducing new surcharges, ending certain last mile e-commerce subsidies, and deploying advanced AI tools to improve efficiency and cost control. FedEx has also gained recognition for an e-waste circular economy pilot, highlighting a broader push into sustainability within its logistics...
NasdaqGS:COLB
NasdaqGS:COLBBanks

Is Columbia Banking System (COLB) Pricing Reflect Long Term Value After Recent Share Price Gains

If you are wondering whether Columbia Banking System's current share price lines up with its underlying value, this article will walk through the key pieces you need to look at. The stock recently closed at US$31.24, with returns of 8.1% over the last 30 days and 19.9% over the past year, which may have shifted how investors view its growth prospects and risk. Recent headlines around Columbia Banking System have largely focused on broader sector themes and company specific updates that...
NYSE:WLY
NYSE:WLYMedia

Does Wiley’s Advanced Portfolio Expansion Into Life Sciences Reshape The Bull Case For John Wiley & Sons (WLY)?

In February 2026, John Wiley & Sons announced a major expansion of its Advanced Portfolio, planning to launch eight new life, health, and social sciences journals by the end of 2026, starting with Advanced Oncology opening for submissions shortly after the announcement. This move turns the Advanced Portfolio from a materials science specialist into a broader multidisciplinary platform, aiming to give researchers a streamlined, single-submission publishing experience across physical, life,...
NYSE:FDP
NYSE:FDPFood

Fresh Del Monte Produce (FDP) Earnings Hit One Off Loss That Fuels Margin Debate

Fresh Del Monte Produce (FDP) has reported a mixed set of FY 2025 numbers, with Q3 revenue of US$1.0b and a basic EPS loss of US$0.61, set against trailing 12 month EPS of US$1.65 and net income of US$79.2m. The company has seen quarterly revenue move between US$1.0b and US$1.2b over the last six reported periods, while basic EPS has ranged from a loss of US$0.61 to a high of US$1.18. The latest quarter therefore lands at the weaker end of that spectrum and leaves investors focused on how...
NYSE:CHE
NYSE:CHEHealthcare

Assessing Chemed (CHE) Valuation After New US$300 Million Buyback And Ongoing Dividend Streak

Chemed (CHE) has put shareholder returns back in focus after boosting its equity buyback authorization by US$300 million and reaffirming a US$0.60 quarterly dividend, maintaining a long running payout record. See our latest analysis for Chemed. Those buyback and dividend decisions come after a solid 90 day share price return of 8.93% and a 10.35% year to date share price gain, even though the 1 year total shareholder return is 15.45% lower. This suggests that recent momentum contrasts with...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

Is It Time To Reassess CoreWeave (CRWV) After AI Infrastructure Backlog Headlines?

If you are asking yourself whether CoreWeave is fairly priced at its current level, this article will walk you through what the numbers suggest about that question. The stock recently closed at US$95.45, with a 0.3% return over 7 days, a 5.7% decline over 30 days and a 20.3% gain year to date. These moves may signal changing views on both its growth potential and risk. Recent headlines have focused on CoreWeave's position in AI infrastructure and cloud services, as investors continue to...
NYSE:AWR
NYSE:AWRWater Utilities

How Investors May Respond To American States Water (AWR) Earnings, Dividend Hike, And Infrastructure Spending Plan

In the past week, American States Water Company reported fourth-quarter 2025 sales of US$164.28 million and net income of US$28.74 million, alongside full-year 2025 revenue of US$658.07 million and earnings per share of US$3.37 from continuing operations. The company paired this steady profit performance with another quarterly dividend increase to US$0.5040 per share and plans for substantial, regulator-supported infrastructure investment, underscoring its focus on long-term capital...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid Group Leans Into Autonomous Software Partnerships As Fleet Risks Mount

Lucid Group (NasdaqGS:LCID) is shifting its long term focus toward software and autonomous driving partnerships, aiming to prioritize software and AI development over pure vehicle sales. The company has entered a major partnership with Uber and Nuro to deploy a large fleet of autonomous premium EVs, supported by a substantial investment from Uber. Lucid is making several high level executive appointments to strengthen global supply chain and engineering leadership as it works to execute this...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

Assessing AST SpaceMobile (ASTS) Valuation After Convertible Notes Deal And BlueBird 6 Milestone

AST SpaceMobile (ASTS) has put two big issues on the table at once: a US$1b low coupon convertible notes deal that reshapes its capital structure, and the successful deployment of its BlueBird 6 satellite. See our latest analysis for AST SpaceMobile. Those financing moves and the BlueBird 6 deployment come after a volatile run, with a 66.53% 3 month share price return and a very large 3 year total shareholder return of about 13x. However, recent 1 month and 7 day share price declines suggest...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Is Revolution Medicines (RVMD) Pricing In Pipeline Progress After A 135.7% One Year Surge?

If you are wondering whether Revolution Medicines at around US$99.79 is priced for its future potential or getting ahead of itself, you are in the right place for a clear look at what the current valuation is really telling you. The stock has had a mixed run recently, with a 1.8% gain over the last 7 days, a 17.0% decline over the past month, a 26.3% year to date return, and 135.7% over the last year, along with a very large 3 year return that sits just under 3x. These moves sit against a...
NYSE:ASGN
NYSE:ASGNIT

Assessing ASGN (ASGN) Valuation After Federal Leadership Move And New Cloud FinOps Partnership

ASGN (ASGN) has returned to focus after appointing federal services veteran Donnie Scott to lead its Federal Segment and announcing a new cloud FinOps partnership between Apex Systems and Cloudaware targeting enterprise cost management needs. See our latest analysis for ASGN. The latest management changes and cloud partnership arrive as ASGN’s 1-day share price return of 4.53% contrasts with a 30-day share price return decline of 11.95% and a 1-year total shareholder return loss of 40.56%...
NYSE:AVA
NYSE:AVAIntegrated Utilities

Assessing Avista (AVA) Valuation After Idaho Electricity Rate Increase Request

Idaho rate case puts Avista (AVA) in focus Avista (AVA) has filed for an annual electric rate adjustment with the Idaho Public Utilities Commission, seeking a 7.4% revenue increase tied to funding electric energy efficiency programs. See our latest analysis for Avista. Avista’s recent Idaho rate case comes as the stock’s share price return is up 4.95% over 30 days and 8.91% year to date, while its 1 year total shareholder return of 18.58% points to steady, if moderate, momentum rather than a...
NYSE:KSS
NYSE:KSSMultiline Retail

Did Kohl’s New Under‑$10 “Deal Bar” Just Shift Kohl's (KSS) Investment Narrative?

Kohl’s recently introduced a new “Deal Bar” section at the front of all its stores, offering gifts, seasonal items, and everyday essentials priced at US$10 or less to appeal to cost-conscious shoppers. This move underlines Kohl’s push to revive store traffic by foregrounding sharply priced impulse and necessity purchases as consumers trim discretionary spending. Next, we’ll examine how the new under-US$10 Deal Bar concept could influence Kohl’s turnaround-focused investment narrative and...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Why Rivian (RIVN) Is Up 15.4% After Mixed Q4 Results And A VW-Funded Tech Pivot

Rivian Automotive reported fourth-quarter 2025 revenue of US$1,286 million, down from US$1,734 million a year earlier, with a net loss of US$811 million, while full-year revenue rose to US$5,387 million and the annual net loss narrowed to US$3,646 million. Alongside these results, Rivian filed a US$1.10 billion shelf registration for ESOP-related Class A shares and highlighted growing software revenue and funding from its Volkswagen joint venture, underscoring its shift toward a technology...